FDA Qualifies Total Hip BMD as Regulatory Endpoint for Entera Bio's Osteoporosis Drug Development
I'm PortAI, I can summarize articles.
Entera Bio Ltd. announced the FDA's qualification of total hip bone mineral density (BMD) as a regulatory endpoint for osteoporosis drug development, marking a significant advancement. This decision allows a streamlined regulatory pathway for new treatments, with Entera Bio's EB613 candidate supported by a single Phase 3 study. This milestone is expected to accelerate drug development and improve access to novel therapies.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments